

1 HIGHLIGHTS OF PRESCRIBING INFORMATION

2 These highlights do not include all the information needed to use Teflaro  
3 safely and effectively. See full prescribing information for Teflaro™.

4 TEFLARO™ (ceftaroline fosamil) injection for intravenous (IV) use

5 Initial U.S. Approval: 2010

6 To reduce the development of drug-resistant bacteria and maintain the  
7 effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only  
8 to treat infections that are proven or strongly suspected to be caused by bacteria.

9 -----INDICATIONS AND USAGE-----

10 -----  
11 Teflaro™ is a cephalosporin antibacterial indicated for the treatment of the  
12 following infections caused by designated susceptible bacteria:

- 13 • Acute bacterial skin and skin structure infections (ABSSI) (1.1)
- 14 • Community-acquired bacterial pneumonia (CABP) (1.2)

15 -----DOSAGE AND ADMINISTRATION-----

- 16 -----
- 17 • 600 mg every 12 hours by IV infusion administered over 1 hour in adults ≥ 18  
18 years of age (2.1)
- 19 • Dosage adjustment in patients with renal impairment (2.2)

Estimated Creatinine Clearance# (mL/min)	Teflaro Dosage Regimen
> 50	No dosage adjustment necessary
> 30 to ≤ 50	400 mg IV (over 1 hour) every 12 hours
≥ 15 to ≤ 30	300 mg IV (over 1 hour) every 12 hours
End-stage renal disease (ESRD), including hemodialysis	200 mg IV (over 1 hour) every 12 hours

20 # As calculated using the Cockcroft-Gault formula

21 -----DOSAGE FORMS AND STRENGTHS-----

22 -----  
23 600 mg or 400 mg of sterile Teflaro powder in single-use 20 mL vials. (3)

24 -----CONTRAINDICATIONS-----

- 25 -----
- 26 • Known serious hypersensitivity to ceftaroline or other members of  
27 the cephalosporin class. (4)

28 -----WARNINGS AND PRECAUTIONS-----

- 29 -----
- 30 • Serious hypersensitivity (anaphylactic) reactions have been  
31 reported with beta-lactam antibiotics, including ceftaroline.  
32 Exercise caution in patients with known hypersensitivity to beta-  
33 lactam antibiotics. (5.1)
- 34 • *Clostridium difficile*-associated diarrhea (CDAD) has been  
35 reported with nearly all systemic antibacterial agents, including  
36 Teflaro. Evaluate if diarrhea occurs. (5.2)
- 37 • Direct Coombs' test seroconversion has been reported with  
38 Teflaro. If anemia develops during or after therapy, a diagnostic  
39 workup for drug-induced hemolytic anemia should be performed  
40 and consideration given to discontinuation of Teflaro. (5.3)

41 -----ADVERSE REACTIONS-----

42 -----  
43 The most common adverse reactions occurring in >2 % of patients are  
44 diarrhea, nausea, and rash. (6.3)

45  
46 To report SUSPECTED ADVERSE REACTIONS, contact Forest  
47 Pharmaceuticals, Inc., at 1-800-678-1605 or FDA at 1-800-FDA-  
48 1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

49 -----USE IN SPECIFIC POPULATIONS-----

- 50 -----
- 51 • Dosage adjustment is required in patients with moderate or severe  
52 renal impairment and in ESRD patients, including patients on  
53 hemodialysis. (2.2, 12.3)

54  
55 See 17 for PATIENT COUNSELING INFORMATION

Revised: January 2011

56  
57  
58 FULL PRESCRIBING INFORMATION: CONTENTS\*

59 1 INDICATIONS AND USAGE

- 60 1.1 Acute Bacterial Skin and Skin Structure Infections
- 61 1.2 Community-Acquired Bacterial Pneumonia
- 62 1.3 Usage

63 2 DOSAGE AND ADMINISTRATION

- 64 2.1 Recommended Dosage
- 65 2.2 Patients with Renal Impairment
- 66 2.3 Preparation of Solutions

67 3 DOSAGE FORMS AND STRENGTHS

68 4 CONTRAINDICATIONS

69 5 WARNINGS AND PRECAUTIONS

- 70 5.1 Hypersensitivity Reactions
- 71 5.2 *Clostridium difficile*-associated Diarrhea
- 72 5.3 Direct Coombs' Test Seroconversion
- 73 5.4 Development of Drug-Resistant Bacteria

74 6 ADVERSE REACTIONS

- 75 6.1 Adverse Reactions from Clinical Trials
- 76 6.2 Serious Adverse Events and Adverse  
77 Events Leading to Discontinuation
- 78 6.3 Most Common Adverse Reactions
- 79 6.4 Other Adverse Reactions Observed During  
80 Clinical Trials of Teflaro

81 7 DRUG INTERACTIONS

82 8 USE IN SPECIFIC POPULATIONS

- 83 8.1 Pregnancy
- 84 8.3 Nursing Mothers
- 85 8.4 Pediatric Use
- 86 8.5 Geriatric Use

88 8.6 Patients with Renal Impairment

89 10 OVERDOSAGE

90 11 DESCRIPTION

91 12 CLINICAL PHARMACOLOGY

- 92 12.1 Mechanism of Action
- 93 12.2 Pharmacodynamics
- 94 12.3 Pharmacokinetics
- 95 12.4 Microbiology

96 13 NONCLINICAL TOXICOLOGY

- 97 13.1 Carcinogenesis, Mutagenesis, Impairment of  
98 Fertility

99 14 CLINICAL TRIALS

- 100 14.1 Acute Bacterial Skin and Skin Structure  
101 Infections
- 102 14.2 Community-Acquired Bacterial Pneumonia

103 15 REFERENCES

104 16 HOW SUPPLIED/STORAGE AND HANDLING

105 17 PATIENT COUNSELING INFORMATION

106  
107  
108 \*Sections or subsections omitted from the full prescribing information  
109 are not listed.

110 **FULL PRESCRIBING INFORMATION**

111 **1. INDICATIONS AND USAGE**

112 Teflaro™ (ceftaroline fosamil) is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated  
113 microorganisms.

114 **1.1 Acute Bacterial Skin and Skin Structure Infections**

115 Teflaro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-  
116 positive and Gram-negative microorganisms: *Staphylococcus aureus* (including methicillin-susceptible and -resistant isolates), *Streptococcus pyogenes*,  
117 *Streptococcus agalactiae*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca*.

118 **1.2 Community-Acquired Bacterial Pneumonia**

119 Teflaro is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive  
120 and Gram-negative microorganisms: *Streptococcus pneumoniae* (including cases with concurrent bacteremia), *Staphylococcus aureus* (methicillin-  
121 susceptible isolates only), *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, and *Escherichia coli*.

122 **1.3 Usage**

123 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used to  
124 treat only ABSSSI or CABP that are proven or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological  
125 examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline. When culture  
126 and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local  
127 epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

128 **2. DOSAGE AND ADMINISTRATION**

129 **2.1 Recommended Dosage**

130 The recommended dosage of Teflaro is 600 mg administered every 12 hours by intravenous (IV) infusion over 1 hour in patients ≥ 18 years of age. The  
131 duration of therapy should be guided by the severity and site of infection and the patient's clinical and bacteriological progress.

132 The recommended dosage and administration by infection is described in Table 1.

133 **Table 1: Dosage of Teflaro by Infection**

Infection	Dosage	Frequency	Infusion Time (hours)	Recommended Duration of Total Antimicrobial Treatment
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)	600 mg	Every 12 hours	1	5-14 days
Community-Acquired Bacterial Pneumonia (CABP)	600 mg	Every 12 hours	1	5-7 days

134  
135 **2.2 Patients with Renal Impairment**

136 **Table 2: Dosage of Teflaro in Patients with Renal Impairment**

Estimated CrCl <sup>a</sup> (mL/min)	Recommended Dosage Regimen for Teflaro
> 50	No dosage adjustment necessary
> 30 to ≤ 50	400 mg IV (over 1 hour) every 12 hours
≥ 15 to ≤ 30	300 mg IV (over 1 hour) every 12 hours
End-stage renal disease, including hemodialysis <sup>b</sup>	200 mg IV (over 1 hour) every 12 hours <sup>c</sup>

137 <sup>a</sup> Creatinine clearance (CrCl) estimated using the Cockcroft-Gault formula.

138 <sup>b</sup> End-stage renal disease is defined as CrCl < 15 mL/min.

139 <sup>c</sup> Teflaro is hemodialyzable; thus Teflaro should be administered after hemodialysis on hemodialysis days.

140 **2.3 Preparation of Solutions**

141 Aseptic technique must be followed in preparing the infusion solution. The contents of Teflaro vial should be constituted with 20 mL Sterile Water for  
142 Injection, USP. The preparation of Teflaro solutions is summarized in Table 3.

**Table 3: Preparation of Teflaro for Intravenous Use**

Dosage Strength (mg)	Volume of Diluent To Be Added (mL)	Approximate Ceftaroline fosamil Concentration (mg/mL)	Amount to Be Withdrawn
400	20	20	Total Volume
600	20	30	Total Volume

145

146

147

148

The constituted solution must be further diluted in 250 mL before infusion. Appropriate infusion solutions include: 0.9% Sodium Chloride Injection, USP (normal saline); 5% Dextrose Injection, USP; 2.5% Dextrose Injection, USP, and 0.45% Sodium Chloride Injection, USP; or Lactated Ringer's Injection, USP. The resulting solution should be administered over approximately 1 hour.

149

150

Constitution time is less than 2 minutes. Mix gently to constitute and check to see that the contents have dissolved completely. Parenteral drug products should be inspected visually for particulate matter prior to administration.

151

152

The color of Teflaro infusion solutions ranges from clear, light to dark yellow depending on the concentration and storage conditions. When stored as recommended, the product potency is not affected.

153

154

Studies have shown that the constituted solution in the infusion bag should be used within 6 hours when stored at room temperature or within 24 hours when stored under refrigeration at 2 to 8° C (36 to 46° F).

155

156

The compatibility of Teflaro with other drugs has not been established. Teflaro should not be mixed with or physically added to solutions containing other drugs.

157

### 3. DOSAGE FORMS AND STRENGTHS

158

Teflaro is supplied in single-use, clear glass vials containing either 600 mg or 400 mg of sterile ceftaroline fosamil powder.

159

### 4. CONTRAINDICATIONS

160

161

Teflaro is contraindicated in patients with known serious hypersensitivity to ceftaroline or other members of the cephalosporin class. Anaphylaxis and anaphylactoid reactions have been reported with ceftaroline.

162

### 5. WARNINGS AND PRECAUTIONS

163

#### 5.1 Hypersensitivity Reactions

164

165

166

167

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterials. Before therapy with Teflaro is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems should be made. If this product is to be given to a penicillin- or other beta-lactam-allergic patient, caution should be exercised because cross sensitivity among beta-lactam antibacterial agents has been clearly established.

168

169

170

If an allergic reaction to Teflaro occurs, the drug should be discontinued. Serious acute hypersensitivity (anaphylactic) reactions require emergency treatment with epinephrine and other emergency measures, that may include airway management, oxygen, intravenous fluids, antihistamines, corticosteroids, and vasopressors as clinically indicated.

171

#### 5.2 *Clostridium difficile*-associated Diarrhea

172

173

*Clostridium difficile*-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.

174

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of *C. difficile*.

175

176

177

178

*C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents.

179

180

181

If CDAD is suspected or confirmed, antibacterials not directed against *C. difficile* should be discontinued, if possible. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated [see *Adverse Reactions* (6.3)].

182

#### 5.3 Direct Coombs' Test Seroconversion

183

184

Seroconversion from a negative to a positive direct Coombs' test result occurred in 120/1114 (10.8%) of patients receiving Teflaro and 49/1116 (4.4%) of patients receiving comparator drugs in the four pooled Phase 3 trials.

185

186

In the pooled Phase 3 CABP trials, 51/520 (9.8%) of Teflaro-treated patients compared to 24/534 (4.5%) of ceftriaxone-treated patients seroconverted from a negative to a positive direct Coombs' test result. No adverse reactions representing hemolytic anemia were reported in any treatment group.

187

188

189

If anemia develops during or after treatment with Teflaro, drug-induced hemolytic anemia should be considered. Diagnostic studies including a direct Coombs' test, should be performed. If drug-induced hemolytic anemia is suspected, discontinuation of Teflaro should be considered and supportive care should be administered to the patient (i.e. transfusion) if clinically indicated.

190

191

192 **5.4 Development of Drug-Resistant Bacteria**

193 Prescribing Teflaro in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk  
 194 of the development of drug-resistant bacteria.

195 **6. ADVERSE REACTIONS**

196 The following serious events are described in greater detail in the Warnings and Precautions section

- 197 • Hypersensitivity reactions [see Warnings and Precautions (5.1)]
- 198 • *Clostridium difficile*-associated diarrhea [see Warnings and Precautions (5.2)]
- 199 • Direct Coombs' test seroconversion [see Warnings and Precautions (5.3)]

200 **6.1 Adverse Reactions from Clinical Trials**

201 Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be compared  
 202 directly to rates from clinical trials of another drug and may not reflect rates observed in practice.

203 Teflaro was evaluated in four controlled comparative Phase 3 clinical trials (two in ABSSSI and two in CABP) which included 1300 adult patients treated  
 204 with Teflaro (600 mg administered by IV over 1 hour every 12h) and 1297 patients treated with comparator (vancomycin plus aztreonam or ceftriaxone)  
 205 for a treatment period up to 21 days. The median age of patients treated with Teflaro was 54 years, ranging between 18 and 99 years old. Patients treated  
 206 with Teflaro were predominantly male (63%) and Caucasian (82%).

207 **6.2 Serious Adverse Events and Adverse Events Leading to Discontinuation**

208 In the four pooled Phase 3 clinical trials, serious adverse events occurred in 98/1300 (7.5%) of patients receiving Teflaro and 100/1297 (7.7%) of patients  
 209 receiving comparator drugs. The most common SAEs in both the Teflaro and comparator treatment groups were in the respiratory and infection system  
 210 organ classes (SOC). Treatment discontinuation due to adverse events occurred in 35/1300 (2.7%) of patients receiving Teflaro and 48/1297 (3.7%) of  
 211 patients receiving comparator drugs with the most common adverse events leading to discontinuation being hypersensitivity for both treatment groups at a  
 212 rate of 0.3% in the Teflaro group and 0.5% in comparator group.

213 **6.3 Most Common Adverse Reactions**

214 No adverse reactions occurred in greater than 5% of patients receiving Teflaro. The most common adverse reactions occurring in > 2% of patients  
 215 receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.

216 Table 4 lists adverse reactions occurring in ≥ 2% of patients receiving Teflaro in the pooled Phase 3 clinical trials.

217 **Table 4: Adverse Reactions Occurring in ≥ 2% of Patients Receiving Teflaro in the Pooled Phase 3 Clinical Trials**

System Organ Class/ Preferred Term	Pooled Phase 3 Clinical Trials (four trials, two in ABSSSI and two in CABP)	
	Teflaro (N=1300)	Pooled Comparators <sup>a</sup> (N=1297)
<b>Gastrointestinal disorders</b>		
Diarrhea	5 %	3 %
Nausea	4 %	4 %
Constipation	2 %	2 %
Vomiting	2 %	2 %
<b>Investigations</b>		
Increased transaminases	2%	3 %
<b>Metabolism and nutrition disorders</b>		
Hypokalemia	2 %	3 %
<b>Skin and subcutaneous tissue disorders</b>		
Rash	3%	2%
<b>Vascular disorders</b>		
Phlebitis	2%	1%

218 <sup>a</sup> Comparators included vancomycin 1 gram IV every 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trials, and ceftriaxone 1 gram  
 219 IV every 24h in the Phase 3 CABP trials.

220  
221

222 **6.4 Other Adverse Reactions Observed During Clinical Trials of Teflaro**

223 Following is a list of additional adverse reactions reported by the 1740 patients who received Teflaro in any clinical trial with incidences less than 2%.  
224 Events are categorized by System Organ Class.

225 **Blood and lymphatic system disorders** - Anemia, Eosinophilia, Neutropenia, Thrombocytopenia

226 **Cardiac disorders** - Bradycardia, Palpitations

227 **Gastrointestinal disorders** - Abdominal pain

228 **General disorders and administration site conditions** - Pyrexia

229 **Hepatobiliary disorders** - Hepatitis

230 **Immune system disorders** - Hypersensitivity, Anaphylaxis

231 **Infections and infestations** - *Clostridium difficile* colitis

232 **Metabolism and nutrition disorders** - Hyperglycemia, Hyperkalemia

233 **Nervous system disorders** - Dizziness, Convulsion

234 **Renal and urinary disorders** - Renal failure

235 **Skin and subcutaneous tissue disorders** - Urticaria

236 **7. DRUG INTERACTIONS**

237 No clinical drug-drug interaction studies have been conducted with Teflaro. There is minimal potential for drug-drug interactions between Teflaro and  
238 CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow [see *Clinical*  
239 *Pharmacology (12.3)*].

240 **8. USE IN SPECIFIC POPULATIONS**

241 **8.1 Pregnancy**

242 **Category B**

243 Developmental toxicity studies performed with ceftaroline fosamil in rats at IV doses up to 300 mg/kg demonstrated no maternal toxicity and no effects  
244 on the fetus. A separate toxicokinetic study showed that ceftaroline exposure in rats (based on AUC) at this dose level was approximately 8 times the  
245 exposure in humans given 600 mg every 12 hours. There were no drug-induced malformations in the offspring of rabbits given IV doses of 25, 50, and  
246 100 mg/kg, despite maternal toxicity. Signs of maternal toxicity appeared secondary to the sensitivity of the rabbit gastrointestinal system to broad-  
247 spectrum antibacterials and included changes in fecal output in all groups and dose-related reductions in body weight gain and food consumption at  $\geq 50$   
248 mg/kg; these were associated with an increase in spontaneous abortion at 50 and 100 mg/kg. The highest dose was also associated with maternal  
249 moribundity and mortality. An increased incidence of a common rabbit skeletal variation, angulated hyoid alae, was also observed at the maternally toxic  
250 doses of 50 and 100 mg/kg. A separate toxicokinetic study showed that ceftaroline exposure in rabbits (based on AUC) was approximately 0.8 times the  
251 exposure in humans given 600 mg every 12 hours at 25 mg/kg and 1.5 times the human exposure at 50 mg/kg.

252 Ceftaroline fosamil did not affect the postnatal development or reproductive performance of the offspring of rats given IV doses up to 450 mg/kg/day.  
253 Results from a toxicokinetic study conducted in pregnant rats with doses up to 300 mg/kg suggest that exposure was  $\geq 8$  times the exposure in humans  
254 given 600 mg every 12 hours.

255 There are no adequate and well-controlled trials in pregnant women. Teflaro should be used during pregnancy only if the potential benefit justifies the  
256 potential risk to the fetus.

257 **8.3 Nursing Mothers**

258 It is not known whether ceftaroline is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Teflaro  
259 is administered to a nursing woman.

260 **8.4 Pediatric Use**

261 Safety and effectiveness in pediatric patients have not been established.

262 **8.5 Geriatric Use**

263 Of the 1300 patients treated with Teflaro in the Phase 3 ABSSSI and CABP trials, 397 (30.5%) were  $\geq 65$  years of age. The clinical cure rates in the  
264 Teflaro group (Clinically Evaluable [CE] Population) were similar in patients  $\geq 65$  years of age compared with patients  $< 65$  years of age in both the  
265 ABSSSI and CABP trials.

266 The adverse event profiles in patients  $\geq 65$  years of age and in patients  $< 65$  years of age were similar. The percentage of patients in the Teflaro group who  
267 had at least one adverse event was 52.4% in patients  $\geq 65$  years of age and 42.8% in patients  $< 65$  years of age for the two indications combined.

268 Ceftaroline is excreted primarily by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly  
269 patients are more likely to have decreased renal function, care should be taken in dose selection in this age group and it may be useful to monitor renal  
270 function. Elderly subjects had greater ceftaroline exposure relative to non-elderly subjects when administered the same single dose of Teflaro. However,  
271 higher exposure in elderly subjects was mainly attributed to age-related changes in renal function. Dosage adjustment for elderly patients should be based  
272 on renal function [see *Dosage and Administration (2.2) and Clinical Pharmacology (12.3)*].

273

274

275 **8.6 Patients with Renal Impairment**

276 Dosage adjustment is required in patients with moderate (CrCl > 30 to ≤ 50 mL/min) or severe (CrCl ≥ 15 to ≤ 30 mL/min) renal impairment and in  
277 patients with end-stage renal disease (ESRD – defined as CrCl < 15 mL/min), including patients on hemodialysis (HD) [see *Dosage and Administration*  
278 (2.2) and *Clinical Pharmacology* (12.3)].

279 **10. OVERDOSAGE**


280 In the event of overdose, Teflaro should be discontinued and general supportive treatment given.

281 Ceftaroline can be removed by hemodialysis. In subjects with ESRD administered 400 mg of Teflaro, the mean total recovery of ceftaroline in the  
282 dialysate following a 4-hour hemodialysis session started 4 hours after dosing was 76.5 mg (21.6% of the dose). However, no information is available on  
283 the use of hemodialysis to treat overdose [see *Clinical Pharmacology* (12.3)].

284 **11. DESCRIPTION**

285 Teflaro is a sterile, semi-synthetic, broad-spectrum, prodrug antibacterial of cephalosporin class of beta-lactams (β-lactams). Chemically, the prodrug,  
286 ceftaroline fosamil monoacetate monohydrate is (6*R*,7*R*)-7-[(2*Z*)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetamido]-3-[[4-(1-  
287 methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate monoacetate monohydrate. Its molecular  
288 weight is 762.75. The empirical formula is C<sub>22</sub>H<sub>21</sub>N<sub>8</sub>O<sub>8</sub>PS<sub>4</sub>·C<sub>2</sub>H<sub>4</sub>O<sub>2</sub>·H<sub>2</sub>O.

289 **Figure 1: Chemical structure of ceftaroline fosamil**



300 Teflaro vials contain either 600 mg or 400 mg of anhydrous ceftaroline fosamil. The powder for injection is formulated from ceftaroline fosamil  
301 monoacetate monohydrate, a pale yellowish-white to light yellow sterile powder. All references to ceftaroline activity are expressed in terms of the  
302 prodrug, ceftaroline fosamil. The powder is constituted for IV injection [see *Dosage and Administration* (2.3)].

303 Each vial of Teflaro contains ceftaroline fosamil and L-arginine, which results in a constituted solution at pH 4.8 to 6.5.

304 **12. CLINICAL PHARMACOLOGY**

305 Ceftaroline fosamil is the water-soluble prodrug of the bioactive ceftaroline [see *Clinical Pharmacology* (12.3)].

306 **12.1 Mechanism of Action**

307 Ceftaroline is an antibacterial drug [see *Clinical Pharmacology* (12.4)].

308 **12.2 Pharmacodynamics**

309 As with other beta-lactam antimicrobial agents, the time that unbound plasma concentration of ceftaroline exceeds the minimum inhibitory concentration  
310 (MIC) of the infecting organism has been shown to best correlate with efficacy in a neutropenic murine thigh infection model with *S. aureus* and *S.*  
311 *pneumoniae*.

312 Exposure-response analysis of Phase 2/3 ABSSSI trials supports the recommended dosage regimen of Teflaro 600 mg every 12 hours by IV infusion over  
313 1 hour. For Phase 3 CABP trials, an exposure-response relationship could not be identified due to the limited range of ceftaroline exposures in the  
314 majority of patients.

315 **Cardiac Electrophysiology**

316 In a randomized, positive- and placebo-controlled crossover thorough QTc study, 54 healthy subjects were each administered a single dose of Teflaro  
317 1500 mg, placebo, and a positive control by IV infusion over 1 hour. At the 1500 mg dose of Teflaro, no significant effect on QTc interval was detected at  
318 peak plasma concentration or at any other time.

319 **12.3 Pharmacokinetics**

320 The mean pharmacokinetic parameters of ceftaroline in healthy adults (n=6) with normal renal function after single and multiple 1-hour IV infusions of  
321 600 mg ceftaroline fosamil administered every 12 hours are summarized in Table 5. Pharmacokinetic parameters were similar for single and multiple dose  
322 administration.

323  
324  
325

**Table 5: Mean (Standard Deviation) Pharmacokinetic Parameters of Ceftaroline IV in Healthy Adults**

Parameter	Single 600 mg Dose Administered as a 1-Hour Infusion(n=6)	Multiple 600 mg Doses Administered Every 12 Hours as 1-Hour Infusions for 14 Days(n=6)
$C_{max}$ (mcg/mL)	19.0 (0.71)	21.3 (4.10)
$T_{max}$ (h) <sup>a</sup>	1.00 (0.92-1.25)	0.92 (0.92-1.08)
AUC (mcg•h/mL) <sup>b</sup>	56.8 (9.31)	56.3 (8.90)
$T_{1/2}$ (h)	1.60 (0.38)	2.66 (0.40)
CL (L/h)	9.58 (1.85)	9.60 (1.40)
<sup>a</sup> Reported as median (range)		
<sup>b</sup> AUC <sub>0-∞</sub> , for single-dose administration; AUC <sub>0-tau</sub> , for multiple-dose administration; C <sub>max</sub> , maximum observed concentration; T <sub>max</sub> , time of C <sub>max</sub> ; AUC <sub>0-∞</sub> , area under concentration-time curve from time 0 to infinity; AUC <sub>0-tau</sub> , area under concentration-time curve over dosing interval (0-12 hours); T <sub>1/2</sub> , terminal elimination half-life; CL, plasma clearance		

327

328

329

330

The  $C_{max}$  and AUC of ceftaroline increase approximately in proportion to dose within the single dose range of 50 to 1000 mg. No appreciable accumulation of ceftaroline is observed following multiple IV infusions of 600 mg administered every 12 hours for up to 14 days in healthy adults with normal renal function.

331

### Distribution

332

333

334

The average binding of ceftaroline to human plasma proteins is approximately 20% and decreases slightly with increasing concentrations over 1-50 mcg/mL (14.5-28.0%). The median (range) steady-state volume of distribution of ceftaroline in healthy adult males (n=6) following a single 600 mg IV dose of radiolabeled ceftaroline fosamil was 20.3 L (18.3-21.6 L), similar to extracellular fluid volume.

335

### Metabolism

336

337

338

339

Ceftaroline fosamil is converted into bioactive ceftaroline in plasma by a phosphatase enzyme and concentrations of the prodrug are measurable in plasma primarily during IV infusion. Hydrolysis of the beta-lactam ring of ceftaroline occurs to form the microbiologically inactive, open-ring metabolite ceftaroline M-1. The mean (SD) plasma ceftaroline M-1 to ceftaroline AUC<sub>0-∞</sub> ratio following a single 600 mg IV infusion of ceftaroline fosamil in healthy adults (n=6) with normal renal function is 28% (3.1%).

340

341

When incubated with pooled human liver microsomes, ceftaroline was metabolically stable (< 12% metabolic turnover), indicating that ceftaroline is not a substrate for hepatic CYP450 enzymes.

342

### Excretion

343

344

345

346

Ceftaroline and its metabolites are primarily eliminated by the kidneys. Following administration of a single 600 mg IV dose of radiolabeled ceftaroline fosamil to healthy male adults (n=6), approximately 88% of radioactivity was recovered in urine and 6% in feces within 48 hours. Of the radioactivity recovered in urine approximately 64% was excreted as ceftaroline and approximately 2% as ceftaroline M-1. The mean (SD) renal clearance of ceftaroline was 5.56 (0.20) L/h, suggesting that ceftaroline is predominantly eliminated by glomerular filtration.

347

### Specific Populations

348

#### Renal Impairment

349

350

351

352

353

354

Following administration of a single 600 mg IV dose of Teflaro, the geometric mean AUC<sub>0-∞</sub> of ceftaroline in subjects with mild (CrCl > 50 to ≤ 80 mL/min, n=6) or moderate (CrCl > 30 to ≤ 50 mL/min, n=6) renal impairment was 19% and 52% higher, respectively, compared to healthy subjects with normal renal function (CrCl > 80 mL/min, n=6). Following administration of a single 400 mg IV dose of Teflaro, the geometric mean AUC<sub>0-∞</sub> of ceftaroline in subjects with severe (CrCl ≥ 15 to ≤ 30 mL/min, n=6) renal impairment was 115% higher compared to healthy subjects with normal renal function (CrCl > 80 mL/min, n=6). Dosage adjustment is recommended in patients with moderate and severe renal impairment [see *Dosage and Administration* (2.2)].

355

356

357

358

A single 400 mg dose of Teflaro was administered to subjects with ESRD (n=6) either 4 hours prior to or 1 hour after hemodialysis (HD). The geometric mean ceftaroline AUC<sub>0-∞</sub> following the post-HD infusion was 167% higher compared to healthy subjects with normal renal function (CrCl > 80 mL/min, n=6). The mean recovery of ceftaroline in the dialysate following a 4-hour HD session was 76.5 mg, or 21.6% of the administered dose. Dosage adjustment is recommended in patients with ESRD (defined as CrCL < 15 mL/min), including patients on HD [see *Dosage and Administration* (2.2)].

359

#### Hepatic Impairment

360

361

The pharmacokinetics of ceftaroline in patients with hepatic impairment have not been established. As ceftaroline does not appear to undergo significant hepatic metabolism, the systemic clearance of ceftaroline is not expected to be significantly affected by hepatic impairment.

362

#### Geriatric Patients

363

364

365

366

Following administration of a single 600 mg IV dose of Teflaro to healthy elderly subjects (≥ 65 years of age, n=16), the geometric mean AUC<sub>0-∞</sub> of ceftaroline was ~33% higher compared to healthy young adult subjects (18-45 years of age, n=16). The difference in AUC<sub>0-∞</sub> was mainly attributable to age-related changes in renal function. Dosage adjustment for Teflaro in elderly patients should be based on renal function [see *Dosage and Administration* (2.2)].

367

368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427

## **Pediatric Patients**

The pharmacokinetics of ceftaroline were evaluated in adolescent patients (ages 12 to 17, n=7) with normal renal function following administration of a single 8 mg/kg IV dose of Teflaro (or 600 mg for subjects weighing > 75 kg). The mean plasma clearance and terminal phase volume of distribution for ceftaroline in adolescent subjects were similar to healthy adults (n=6) in a separate study following administration of a single 600 mg IV dose. However, the mean C<sub>max</sub> and AUC<sub>0-∞</sub> for ceftaroline in adolescent subjects who received a single 8 mg/kg dose were 10% and 23% less than in healthy adult subjects who received a single 600 mg IV dose.

## **Gender**

Following administration of a single 600 mg IV dose of Teflaro to healthy elderly males (n=10) and females (n=6) and healthy young adult males (n=6) and females (n=10), the mean C<sub>max</sub> and AUC<sub>0-∞</sub> for ceftaroline were similar between males and females, although there was a trend for higher C<sub>max</sub> (17%) and AUC<sub>0-∞</sub> (6-15%) in female subjects. Population pharmacokinetic analysis did not identify any significant differences in ceftaroline AUC<sub>0-tau</sub> based on gender in Phase 2/3 patients with ABSSSI or CABP. No dose adjustment is recommended based on gender.

## **Race**

A population pharmacokinetic analysis was performed to evaluate the impact of race on the pharmacokinetics of ceftaroline using data from Phase 2/3 ABSSSI and CABP trials. No significant differences in ceftaroline AUC<sub>0-tau</sub> was observed across White (n=35), Hispanic (n=34), and Black (n=17) race groups for ABSSSI patients. Patients enrolled in CABP trials were predominantly categorized as White (n=115); thus there were too few patients of other races to draw any conclusions. No dosage adjustment is recommended based on race.

## **Drug Interactions**

*In vitro* studies in human liver microsomes indicate that ceftaroline does not inhibit the major cytochrome P450 isoenzymes CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. *In vitro* studies in human hepatocytes also demonstrate that ceftaroline and its inactive open-ring metabolite are not inducers of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4/5. Therefore Teflaro is not expected to inhibit or induce the clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner.

Population pharmacokinetic analysis did not identify any clinically relevant differences in ceftaroline exposure (C<sub>max</sub> and AUC<sub>0-tau</sub>) in Phase 2/3 patients with ABSSSI or CABP who were taking concomitant medications that are known inhibitors, inducers, or substrates of the cytochrome P450 system; anionic or cationic drugs known to undergo active renal secretion; and vasodilator or vasoconstrictor drugs that may alter renal blood flow.

## **12.4 Microbiology**

### **Mode of Action**

Ceftaroline is a cephalosporin with *in vitro* activity against Gram-positive and -negative bacteria. The bactericidal action of ceftaroline is mediated through binding to essential penicillin-binding proteins (PBPs). Ceftaroline is bactericidal against *S. aureus* due to its affinity for PBP2a and against *Streptococcus pneumoniae* due to its affinity for PBP2x.

### **Mechanisms of Resistance**

Ceftaroline is not active against Gram-negative bacteria producing extended spectrum beta-lactamases (ESBLs) from the TEM, SHV or CTX-M families, serine carbapenemases (such as KPC), class B metallo-beta-lactamases, or class C (AmpC cephalosporinases).

### **Cross-Resistance**

Although cross-resistance may occur, some isolates resistant to other cephalosporins may be susceptible to ceftaroline.

### **Interaction with Other Antimicrobials**

*In vitro* studies have not demonstrated any antagonism between ceftaroline or other commonly used antibacterial agents (e.g., vancomycin, linezolid, daptomycin, levofloxacin, azithromycin, amikacin, aztreonam, tigecycline, and meropenem).

Ceftaroline has been shown to be active against most of the following bacteria, both *in vitro* and in clinical infections [see *Indications and Usage (1)*].

### **Skin Infections**

Gram-positive bacteria  
*Staphylococcus aureus* (including methicillin-susceptible and -resistant isolates)  
*Streptococcus pyogenes*  
*Streptococcus agalactiae*

Gram-negative bacteria  
*Escherichia coli*  
*Klebsiella pneumoniae*  
*Klebsiella oxytoca*

### **Community-Acquired Bacterial Pneumonia (CABP)**

Gram-positive bacteria  
*Streptococcus pneumoniae*  
*Staphylococcus aureus* (methicillin-susceptible isolates only)

Gram-negative bacteria  
*Haemophilus influenzae*  
*Klebsiella pneumoniae*  
*Klebsiella oxytoca*

428 *Escherichia coli*

429 The following *in vitro* data are available, but their clinical significance is unknown. Ceftaroline exhibits *in vitro* MICs of 1 mcg/mL or less against most  
430 ( $\geq 90\%$ ) isolates of the following bacteria; however, the safety and effectiveness of Teflaro in treating clinical infections due to these bacteria have not  
431 been established in adequate and well-controlled clinical trials.

432 Gram-positive bacteria  
433 *Streptococcus dysgalactiae*

434  
435 Gram-negative bacteria  
436 *Citrobacter koseri*  
437 *Citrobacter freundii*  
438 *Enterobacter cloacae*  
439 *Enterobacter aerogenes*  
440 *Moraxella catarrhalis*  
441 *Morganella morganii*  
442 *Proteus mirabilis*  
443 *Haemophilus parainfluenzae*  
444

#### 445 **Susceptibility Test Methods**

446 When available, the clinical microbiology laboratory should provide the results of *in vitro* susceptibility test results for antimicrobial drugs used in local  
447 hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens.  
448 These reports should aid the physician in selecting an antibacterial drug product for treatment.

#### 449 **Dilution Techniques**

450 Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility  
451 of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method<sup>1,3</sup>, (broth, and/or agar). Broth dilution MICs  
452 need to be read within 18 hours due to degradation of ceftaroline activity by 24 hours. The MIC values should be interpreted according to the criteria in  
453 Table 6.

#### 454 **Diffusion Techniques**

455 Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial  
456 compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a  
457 standardized method. This procedure uses paper disks impregnated with 30 mcg of ceftaroline to test the susceptibility of bacteria to ceftaroline. The disk  
458 diffusion interpretive criteria are provided in Table 6.

459 **Table 6: Susceptibility Interpretive Criteria for Ceftaroline**

Pathogen and Isolate Source	Minimum Inhibitory Concentrations (mcg/mL)			Disk Diffusion Zone Diameter (mm)		
	S	I	R	S	I	R
<i>Staphylococcus aureus</i> (includes methicillin-resistant isolates - skin isolates only) -See <b>NOTE</b> below	$\leq 1^a$	—	—	$\geq 24$	—	—
<i>Streptococcus agalactiae</i> <sup>a</sup> (skin isolates only)	$\leq 0.03$	—	—	$\geq 26$	—	—
<i>Streptococcus pyogenes</i> <sup>a</sup> (skin isolates only)	$\leq 0.015$	—	—	$\geq 24$	—	—
<i>Streptococcus pneumoniae</i> <sup>a</sup> (CABP isolates only)	$\leq 0.25$	—	—	$\geq 27$	—	—
<i>Haemophilus influenzae</i> (CABP isolates only)	$\leq 0.12$	—	—	$\geq 33$	—	—
<i>Enterobacteriaceae</i> <sup>b</sup> (CABP and skin isolates)	$\leq 0.5$	1	$\geq 2$	$\geq 23$	20-22	$\leq 19$

S = susceptible, I = intermediate, R = resistant

**NOTE:** Clinical efficacy of Teflaro to treat lower respiratory infections such as community-acquired bacterial pneumonia due to MRSA has not been studied in adequate and well controlled trials (See “Clinical Trials” section 14)

<sup>a</sup> The current absence of resistant isolates precludes defining any results other than “Susceptible.” Isolates yielding MIC results other than “Susceptible” should be submitted to a reference laboratory for further testing.

<sup>b</sup> Clinical efficacy was shown for the following *Enterobacteriaceae*: *Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca*.

466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477

A report of “Susceptible” indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration at the infection site necessary to inhibit growth of the pathogen. A report of “Intermediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.

**Quality Control**

Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.<sup>1,2,3</sup> Standard ceftaroline powder should provide the following range of MIC values provided in Table 7. For the diffusion technique using the 30-mcg ceftaroline disk the criteria provided in Table 7 should be achieved.

**Table 7: Acceptable Quality Control Ranges for Susceptibility Testing**

Quality Control Organism	Minimum Inhibitory Concentrations (mcg/mL)	Disk Diffusion (zone diameters in mm)
<i>Staphylococcus aureus</i> ATCC 25923	Not Applicable	26-35
<i>Staphylococcus aureus</i> ATCC 29213	0.12-0.5	Not Applicable
<i>Escherichia coli</i> ATCC 25922	0.03-0.12	26-34
<i>Haemophilus influenzae</i> ATCC 49247	0.03-0.12	29-39
<i>Streptococcus pneumoniae</i> ATCC 49619	0.008-0.03	31-41

ATCC = American Type Culture Collection

478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506

**13. NONCLINICAL TOXICOLOGY**

**13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term carcinogenicity studies have not been conducted with ceftaroline.

Ceftaroline fosamil did not show evidence of mutagenic activity in *in vitro* tests that included a bacterial reverse mutation assay and the mouse lymphoma assay. Ceftaroline was not mutagenic in an *in vitro* mammalian cell assay. *In vivo*, ceftaroline fosamil did not induce unscheduled DNA synthesis in rat hepatocytes and did not induce the formation of micronucleated erythrocytes in mouse or rat bone marrow. Both ceftaroline fosamil and ceftaroline were clastogenic in the absence of metabolic activation in an *in vitro* chromosomal aberration assays, but not in the presence of metabolic activation.

IV injection of ceftaroline fosamil had no adverse effects on fertility of male and female rats given up to 450 mg/kg. This is approximately 4-fold higher than the maximum recommended human dose based on body surface area.

**14. CLINICAL TRIALS**

**14.1 Acute Bacterial Skin and Skin Structure Infections (ABSSI)**

A total of 1396 adults with clinically documented complicated skin and skin structure infection were enrolled in two identical randomized, multi-center, multinational, double-blind, non-inferiority trials (Trials 1 and 2) comparing Teflaro (600 mg administered IV over 1 hour every 12 hours) to vancomycin plus aztreonam (1 g vancomycin administered IV over 1 hour followed by 1 g aztreonam administered IV over 1 hour every 12 hours). Treatment duration was 5 to 14 days. A switch to oral therapy was not allowed. The Modified Intent-to-Treat (MITT) population included all patients who received any amount of study drug according to their randomized treatment group. The CE population included patients in the MITT population who demonstrated sufficient adherence to the protocol.

To evaluate the treatment effect of ceftaroline, an analysis was conducted in 797 patients with ABSSI (such as deep/extensive cellulitis or a wound infection [surgical or traumatic]) for whom the treatment effect of antibacterials may be supported by historical evidence. This analysis evaluated responder rates based on achieving both cessation of lesion spread and absence of fever on Trial Day 3 in the following subgroup of patients:

- Patients with lesion size  $\geq 75$  cm<sup>2</sup> and having one of the following infection types:
  - Major abscess with  $\geq 5$  cm of surrounding erythema
  - Wound infection
  - Deep/extensive cellulitis

The results of this analysis are shown in Table 8.

507

**Table 8: Clinical Responders at Study Day 3 from Two Phase 3 ABSSSI Trials**

	<b>Teflaro n/N (%)</b>	<b>Vancomycin/ Aztreonam n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>ABSSSI Trial 1</b>	148/200 (74.0)	135/209 (64.6)	9.4 (0.4, 18.2)
<b>ABSSSI Trial 2</b>	148/200 (74.0)	128/188 (68.1)	5.9 (-3.1, 14.9)

508

509

510

511

512

The protocol-specified analyses included clinical cure rates at the Test of Cure (TOC) (visit 8 to 15 days after the end of therapy) in the co-primary CE and MITT populations (Table 9) and clinical cure rates at TOC by pathogen in the Microbiologically Evaluable (ME) population (Table 10). However, there are insufficient historical data to establish the magnitude of drug effect for antibacterial drugs compared with placebo at a TOC time point. Therefore, comparisons of Teflaro to vancomycin plus aztreonam based on clinical response rates at TOC can not be utilized to establish non-inferiority.

513

**Table 9: Clinical Cure Rates at TOC from Two Phase 3 ABSSSI Trials**

	<b>Teflaro n/N (%)</b>	<b>Vancomycin/ Aztreonam n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>Trial 1</b>			
<b>CE</b>	288/316 (91.1)	280/300 (93.3)	-2.2 (-6.6, 2.1)
<b>MITT</b>	304/351 (86.6)	297/347 (85.6)	1.0 (-4.2, 6.2)
<b>Trial 2</b>			
<b>CE</b>	271/294 (92.2)	269/292 (92.1)	0.1 (-4.4, 4.5)
<b>MITT</b>	291/342 (85.1)	289/338 (85.5)	-0.4 (-5.8, 5.0)

514

515

516

**Table 10: Clinical Cure Rates at TOC by Pathogen from Two Integrated Phase 3 ABSSSI Trials**

	<b>Teflaro n/N (%)</b>	<b>Vancomycin/Aztreonam n/N (%)</b>
<b>Gram-positive:</b>		
MSSA (methicillin-susceptible)	212/228 (93.0%)	225/238 (94.5%)
MRSA (methicillin-resistant)	142/152 (93.4%)	115/122 (94.3%)
<i>Streptococcus pyogenes</i>	56/56 (100%)	56/58 (96.6%)
<i>Streptococcus agalactiae</i>	21/22 (95.5%)	18/18 (100%)
<b>Gram-negative:</b>		
<i>Escherichia coli</i>	20/21 (95.2%)	19/21 (90.5%)
<i>Klebsiella pneumoniae</i>	17/18 (94.4%)	13/14 (92.9%)
<i>Klebsiella oxytoca</i>	10/12 (83.3%)	6/6 (100%)

517

518

#### 14.2 Community-Acquired Bacterial Pneumonia (CABP)

519

520

521

522

523

524

525

526

A total of 1231 adults with a diagnosis of CABP were enrolled in two randomized, multi-center, multinational, double-blind, non-inferiority trials (Trials 1 and 2) comparing Teflaro (600 mg administered IV over 1 hour every 12 hours) with ceftriaxone (1 g ceftriaxone administered IV over 30 minutes every 24 hours). In both treatment groups of CABP Trial 1, two doses of oral clarithromycin (500 mg every 12 hours), were administered as adjunctive therapy starting on Study Day 1. No adjunctive macrolide therapy was used in CABP Trial 2. Patients with known or suspected MRSA were excluded from both trials. Patients with new or progressive pulmonary infiltrate(s) on chest radiography and signs and symptoms consistent with CABP with the need for hospitalization and IV therapy were enrolled in the trials. Treatment duration was 5 to 7 days. A switch to oral therapy was not allowed. Among all subjects who received any amount of study drug in the two CABP trials, the 30-day all-cause mortality rates were 11/609 (1.8%) for the Teflaro group vs. 12/610 (2.0%) for the ceftriaxone group, and the difference in mortality rates was not statistically significant.

527

528

529

530

531

532

533

To evaluate the treatment effect of ceftaroline, an analysis was conducted in CABP patients for whom the treatment effect of antibacterials may be supported by historical evidence. The analysis endpoint required subjects to meet sign and symptom criteria at Day 4 of therapy: a responder had to both (a) be in stable condition according to consensus treatment guidelines of the Infectious Diseases Society of America and American Thoracic Society, based on temperature, heart rate, respiratory rate, blood pressure, oxygen saturation, and mental status;<sup>4</sup> (b) show improvement from baseline on at least one symptom of cough, dyspnea, pleuritic chest pain, or sputum production, while not worsening on any of these four symptoms. The analysis used a microbiological intent-to-treat population (mITT population) containing only subjects with a confirmed bacterial pathogen at baseline. Results for this analysis are presented in Table 11.

534

**Table 11: Response Rates at Study Day 4 (72-96 hours) from Two Phase 3 CABP Trials**

	<b>Teflaro n/N (%)</b>	<b>Ceftriaxone n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>CABP Trial 1</b>	48/69 (69.6%)	42/72 (58.3%)	11.2 (-4.6, 26.5)
<b>CABP Trial 2</b>	58/84 (69.0%)	51/83 (61.4%)	7.6 (-6.8, 21.8)

535

536

The protocol-specified analyses included clinical cure rates at the TOC (8 to 15 days after the end of therapy) in the co-primary Modified Intent-to-Treat Efficacy (MITTE) and CE populations (Table 12) and clinical cure rates at TOC by pathogen in the Microbiologically Evaluable (ME) population (Table

537  
538  
539  
540  
541  
542

13). However, there are insufficient historical data to establish the magnitude of drug effect for antibacterials drugs compared with placebo at a TOC time point. Therefore, comparisons of Teflaro to ceftriaxone based on clinical response rates at TOC cannot be utilized to establish non-inferiority. Neither trial established that Teflaro was statistically superior to ceftriaxone in terms of clinical response rates. The MITTE population included all patients who received any amount of study drug according to their randomized treatment group and were in PORT (Pneumonia Outcomes Research Team) Risk Class III or IV. The CE population included patients in the MITTE population who demonstrated sufficient adherence to the protocol.

**Table 12: Clinical Cure Rates at TOC from Two Phase 3 CABP Trials**

	<b>Teflaro n/N (%)</b>	<b>Ceftriaxone n/N (%)</b>	<b>Treatment Difference (2-sided 95% CI)</b>
<b>CABP Trial 1</b>			
<b>CE</b>	194/224 (86.6%)	183/234 (78.2%)	8.4 (1.4, 15.4)
<b>MITTE</b>	244/291 (83.8%)	233/300 (77.7%)	6.2 (-0.2, 12.6)
<b>CABP Trial 2</b>			
<b>CE</b>	191/232 (82.3%)	165/214 (77.1%)	5.2 (-2.2, 12.8)
<b>MITTE</b>	231/284 (81.3%)	203/269 (75.5%)	5.9 (-1.0, 12.8)

543

**Table 13: Clinical Cure Rates at TOC by Pathogen from Two Integrated Phase 3 CABP Trials**

	<b>Teflaro n/N (%)</b>	<b>Ceftriaxone n/N (%)</b>
<b>Gram-positive:</b>		
<i>Streptococcus pneumoniae</i>	54/63 (85.7%)	41/59 (69.5%)
<i>Staphylococcus aureus</i> (methicillin-susceptible isolates only)	18/25 (72.0%)	14/25 (56.0%)
<b>Gram-negative:</b>		
<i>Haemophilus influenzae</i>	15/18 (83.3%)	17/20 (85.0%)
<i>Klebsiella pneumoniae</i>	12/12 (100%)	10/12 (83.3%)
<i>Klebsiella oxytoca</i>	5/6 (83.3%)	7/8 (87.5%)
<i>Escherichia coli</i>	10/12 (83.3%)	9/12 (75.0%)

544

**15. REFERENCES**

1. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - 8th ed. Approved Standard, CLSI document M07-A8, CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898. January 2009.
2. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests 10th ed. Approved Standard, CLSI document M02-A10, CLSI, January 2009.
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing 20th Informational Supplement, CLSI document M100-S20, CLSI, January 2010.
4. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., Dowell, S.F., File, T.M., Musher, D.M., Niederman, M.S., Torres, A., Whitney, C.G. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Disease. 2007; 44:S27-72.

545  
546  
547

548  
549

550  
551

552  
553  
554

555

**16. HOW SUPPLIED/STORAGE AND HANDLING**

Teflaro (ceftaroline fosamil) for injection is supplied in single-use, clear glass vials containing:

556  
557  
558

- 600 mg - individual vial (NDC 0456-0600-01) and carton containing 10 vials (NDC 0456-0600-10)
- 400 mg - individual vial (NDC 0456-0400-01) and carton containing 10 vials (NDC 0456-0400-10)

559  
560  
561

Teflaro vials should be stored refrigerated at 2 to 8° C (36 to 46° F). Unrefrigerated, unconstituted Teflaro can be stored at temperatures not exceeding 25°C (77°F) for no more than 7 days.

562

**17. PATIENT COUNSELING INFORMATION**

563  
564  
565

- Patients should be advised that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. They should inform their healthcare provider about any previous hypersensitivity reactions to Teflaro, other beta-lactams (including cephalosporins) or other allergens.

566  
567  
568  
569  
570

- Patients should be counseled that antibacterial drugs including Teflaro should be used to treat only bacterial infections. They do not treat viral infections (e.g., the common cold). When Teflaro is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Teflaro or other antibacterial drugs in the future.

571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591

- Patients should be advised that diarrhea is a common problem caused by antibacterial drugs and usually resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, patients should contact their healthcare provider.

- Keep out of reach of children

Teflaro (ceftaroline fosamil) for injection

**Distributed by:**

Forest Pharmaceuticals, Inc.  
Subsidiary of Forest Laboratories, Inc.  
St. Louis, MO 63045, USA

**Manufactured by:**

Facta Farmaceutici S.p.A.  
Nucleo Industriale S. Atto-S. Nicolò a Tordino  
64020 Teramo, Italy

Teflaro is a trademark of Forest Laboratories, Inc.

**IF95USCFR03**

©2010 Forest Laboratories, Inc. All rights reserved.